American Cyanamid Company

Wyeth

Symphony Evolution, Inc.

Wyeth Holdings Corporation

Philip Frost

Carolyn Mary Discafani-Marro

Allan Wissner

Middleton B Floyd, Jr

Hwei-Ru Tsou

Nan Zhang

Dan Maarten Berger

Philip R Hamann

James J Gibbons, Jr

Gary Dukart

Lisa Anne Speicher

William W N Liao

Eric K Rowinsky

Jeremy Ian Levin

Mark E Salvati

Middleton Brawner Floyd

Yixian Zhang

Lee Greenberger

Philip Ross Hamann

Tammy M Sadler

William Wn Liao

James Joseph Gibbons

Mark Ernest Salvati

Carolyn M Discafani-Marro

Lee Martin Greenberger

Tammy Michelle Sadler

The invention comprises a method of treating polycystic kidney disease (PKD) in a mammal, such as a human or feline (e.g., Persian cat), comprising administering a therapeutically effective amount of the compound of formula to the mammal. Also provided are uses of the compound for preparation of a medicament for treating PKD and the above compound and compositions comprising it for treating PKD.

Use of a receptor-type kinase modulator for treating polycystic kidney disease

The invention comprises use of a therapeutically effective amount of the compound of the formula below for preparation of a medicament for treating polycystic kidney diseases (PKD) in a mammal, such as human or feline (e.g., Persian cat). Formula (I). Also provided are the above compound and compositions comprising it for treating PKD. 

This invention provides compounds of formula I having the structure wherein G, G, R, R, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Substituted 3-cyanoquinolines

This invention provides the use of CCI-779 in the treatment of neoplasms.

Use of CCI-779 as an antineoplastic agent

The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound alone or in combination with an effective amount of an EGF receptor kinase inhibitor.

Method for the treatment of polycystic kidney disease

This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.

Method of treating estrogen receptor positive carcinoma

This invention provides a method of treating or inhibiting colonic polyps or treating or inhibiting colorectal cancer in a mammal in need thereof which comprises administering to said mammal an NSAID and an EFGR kinase inhibitor.

Method of treating or inhibiting colonic polyps and colorectal cancer

Method of treating or inhibiting colonic polyps

This invention provides a method of treating or inhibiting colonic polyps in a mammal in need thereof which comprises administering to said mammal a compound having the formula

This invention provides compounds of formula I having the structure

This invention provides a method of treating or inhibiting polycystic kidney disease in a mammal in need thereof which comprises administering to said mammal a compound having the formula ##STR1## wherein: X is phenyl which is optionally substituted;

Growing community of inventors

Morris Township, NJ, United States of America

Philip Frost